Free Trial
NASDAQ:SKYE

Skye Bioscience (SKYE) Stock Price, News & Analysis

Skye Bioscience logo
$1.82 +0.03 (+1.68%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$1.76 -0.06 (-3.24%)
As of 04/25/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Skye Bioscience Stock (NASDAQ:SKYE)

Key Stats

Today's Range
$1.75
$1.92
50-Day Range
$1.20
$2.30
52-Week Range
$1.14
$13.51
Volume
415,800 shs
Average Volume
349,652 shs
Market Capitalization
$56.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60
Consensus Rating
Buy

Company Overview

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Skye Bioscience Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

SKYE MarketRank™: 

Skye Bioscience scored higher than 20% of companies evaluated by MarketBeat, and ranked 772nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Skye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Skye Bioscience has only been the subject of 2 research reports in the past 90 days.

  • Read more about Skye Bioscience's stock forecast and price target.
  • Earnings Growth

    Earnings for Skye Bioscience are expected to decrease in the coming year, from ($1.04) to ($1.18) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Skye Bioscience is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Skye Bioscience is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    12.71% of the float of Skye Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Skye Bioscience has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Skye Bioscience has recently increased by 10.68%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Skye Bioscience does not currently pay a dividend.

  • Dividend Growth

    Skye Bioscience does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.71% of the float of Skye Bioscience has been sold short.
  • Short Interest Ratio / Days to Cover

    Skye Bioscience has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Skye Bioscience has recently increased by 10.68%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Skye Bioscience has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Skye Bioscience this week, compared to 3 articles on an average week.
  • Search Interest

    4 people have searched for SKYE on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Skye Bioscience insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.00% of the stock of Skye Bioscience is held by insiders.

  • Percentage Held by Institutions

    Only 21.09% of the stock of Skye Bioscience is held by institutions.

  • Read more about Skye Bioscience's insider trading history.
Receive SKYE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SKYE Stock News Headlines

William Blair Comments on Skye Bioscience Q1 Earnings
2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisis
What's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years.
Analysts Offer Predictions for Skye Bioscience Q2 Earnings
Skye Bioscience announces new preclinical data for nimacimab
See More Headlines

SKYE Stock Analysis - Frequently Asked Questions

Skye Bioscience's stock was trading at $2.83 at the start of the year. Since then, SKYE stock has decreased by 35.7% and is now trading at $1.82.
View the best growth stocks for 2025 here
.

Skye Bioscience, Inc. (NASDAQ:SKYE) released its quarterly earnings data on Thursday, March, 20th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.06.
Read the conference call transcript
.

Top institutional investors of Skye Bioscience include Capital Advisors Wealth Management LLC (0.07%). Insiders that own company stock include Punit Dhillon, Paul A Grayson, Kaitlyn Arsenault, Tuan Tu Diep and Andrew J Schwab.
View institutional ownership trends
.

Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG).

Company Calendar

Last Earnings
3/20/2025
Today
4/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SKYE
Previous Symbol
NASDAQ:SKYE
Fax
N/A
Employees
11
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.60
High Stock Price Target
$20.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+812.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.17) per share
Price / Book
-10.71

Miscellaneous

Free Float
29,428,000
Market Cap
$56.37 million
Optionable
Optionable
Beta
1.88
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:SKYE) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners